ArriVent BioPharma, Inc. (AVBP) vs Kardigan, Inc. (KARD)
A side-by-side comparison of ArriVent BioPharma, Inc. and Kardigan, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$13.50HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
KARD
Kardigan, Inc.
$14.19HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — AVBP vs KARD
growth of $100 · dividends reinvested · last 1yAVBP -10.3% (-10.3%/yr)KARD -30.7% (-30.7%/yr)AVBP compounded faster over this window
AVBP KARD
AVBP vs KARD: by the numbers
- •KARD is the larger company ($1.27B vs $629M market cap).
Metrics side by side
Valuation
| Metric | AVBP | KARD |
|---|---|---|
| P/B ratio | 1.71 | 2.06 |
Profitability
| Metric | AVBP | KARD |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | N/A |
| ROIC | -47.96% | -57.11% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.